No 01 2025

Proximity, capital and the ability to scale. When Nordic Life Science reported from life science hubs across Europe, from cities such as Gothenburg, Stockholm, Basel and Barcelona to the Flanders region and the UK as a whole, the same strengths, and the same bottlenecks, kept coming up.

The lab and office section of GoCo Active Lab in Mölndal, outside Gothenburg, has been inaugurated. With CCRM Nordic and several academic partners as tenants, the facility is set to strengthen cell and gene therapy research and development, both regionally and nationally.

Swedish medtech company Getinge raised its adjusted EBITA margin to 15.1% in the third quarter of 2026, from 13.1% a year earlier, while organic sales grew 2.1%. The company kept its forecast of 3–5% organic sales growth for the full year.

Finnish pharmaceutical company Orion has upgraded its full-year 2026 outlook for both net sales and operating profit, as royalty income has grown faster than expected so far this year.

Swedish investment firm EQT has agreed to acquire diagnostics and life science tools company Qiagen through an all-cash public takeover offer, valuing the company at an enterprise value of about EUR 10.8 billion (USD 12.1 billion), including net debt.

Thomas Eldered, co-founder of Recipharm and founder of the investment company Flerie, has been appointed senior advisor to Sciety. He brings more than 35 years of experience from the pharmaceutical industry as an entrepreneur, executive, and investor.

Gesynta Pharma has completed enrollment in NOVA, its Phase II trial of the non-hormonal, non-opioid drug candidate vipoglanstat in endometriosis. The trial is fully enrolled more than three months ahead of schedule, and topline data are expected in the second quarter of 2027.